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Abstract
Scientific and pharmaceutical advancements have revolutionized medicine. Many once- debilitating or fatal diseases can now be 
managed with medication. However, the search for a cure for the inevitable aging diseased state remained futile until recently. 
Rapamycin has been studied for its possible longevity effects, providing promising results for the development of anti-aging therapies. 
This paper evaluates the benefits and risks of rapamycin use. While rapamycin cannot be supported as a safe anti-aging drug, 
rapamycin studies have elucidated parts of the aging pathway, providing a breakthrough for anti-aging research.
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Abbreviations
FKBP - FK506 Binding Protein
AKT – protein kinase B
Introduction 
Hutchinson-Gilford Progeria Syndrome (progeria) is a 
rare genetic disease caused by a mutation on the LMNA 
gene which encodes for the Lamin-A protein. This causes 
a modified form of Lamin-A, known as progerin, which has 
an internal deletion of fifty amino acids (Graziotto et al. 
2012). Wild-type Lamin A is the scaffolding of a cell, which 
holds the nucleus together. Researchers believe the variant 
Lamin-A leads to an unstable nucleus that causes the symp-
toms of progeria (The Progeria Research Foundation).
Children with progeria show early signs of aging, which 
include loss of body fat and hair, growth failure, stiffness of 
joints, aged looking skin, hip dislocation, cardiovascular dis-
ease, stroke, and generalized atherosclerosis. The lifespan 
of children with HGPS is fourteen years, with the common 
cause of death atherosclerosis (The Progeria Research 
Foundation). 
The Progeria Research Foundation is currently con-
ducting a clinical research trial to test a possible cure for 
Progeria. The trial is testing the combined use of Lonafarnib 
and Everolimus on HGPS patients. Lonafarnib is a farnes-
yltransferase inhibitor. By inhibiting the attachment of a 
farsenyl group to progerin, the progerin is unable to in-
hibit the cell function (The Progeria Research Foundation). 
Everolimus, a derivative of rapamycin, promotes the auto-
phagy of the progerin (Graziotto et al. 2012).
Increased levels of progerin have been found in the 
skin and arteries of normal, aged individuals (McClintock 
et al. 2007, Olive et al. 2010). The correlation between 
increased progerin and the physiology of aging is seen in 
the rapid aging of HGPS patients with high levels of pro-
gerin and the decrease in age-associated symptoms upon 
autophagic degeneration of progerin. Thus, the correla-
tion between HGPS and normal aging suggest rapamycin 
as a possible drug to promote longevity in the general 
population (Graziotto et al. 2012).
In 2009, a study showing that rapamycin extends the 
lifespan of mice was published.  This was the first study to 
realize the anti-aging properties of rapamycin on mam-
mals (Harrison et al. 2009). Since then, rapamycin has 
been explored as a possible anti-aging drug for humans. 
Method
Articles sourced in this paper were obtained by searching 
Touro’s database and Google Scholar. Some articles were 
referenced in review articles and the original articles 
were retrieved. Additionally, data was obtained from the 
Progeria Research Foundation and the lecture of Michael 
Hall who discovered and studies TOR.
Discussion  
The Mechanism of Rapamycin
Rapamycin is a macrocyclic lactone secreted by the bacte-
rium streptomyces hygroscopicus which was discovered 
on the Easter Island (Tee 2018). Is was originally intended 
for use as an antifungal. However, its immunosuppressive 
and anti- proliferative properties rendered it unsuitable 
as a safe antifungal treatment. Instead, these properties of 
rapamycin led to its development for other purposes, and 
rapamycin along with its derivatives are FDA approved 
for use as immunosuppressants and an anticancer agent 
(Lamming 2016).
Rapamycin combines with FKBP to inhibit the activity of 
the mechanistic target of rapamycin (mTOR), which is part 
of the phosphatidylinositol 3-kinase-related kinases family 
(Hall 2016). The mTOR protein forms two protein kinase 
complexes - mTORC1 and mTORC2, both balancing cell 
growth and metabolism with degradation.  The mTOR 
pathways responds to favorable growth conditions, such 
as adequate nutrition, resources, and growth factors by 
stimulating anabolic processes (Kennedy, Lamming 2016, 
Laplante, Sabatini 2009). Conversely, stressful conditions 
in the cell inhibit the mTOR pathway, thereby inducing 
catabolic processes (Laplante, Sabatini 2009). 
The two mTOR complexes have some shared compo-
nents. They both contain the mTOR core, the regulatory 
protein Deptor, and mLST8/GβL to ensure complex as-
sembly and stability (Kennedy, Lamming 2016).
In mTORC1, the mTOR protein kinase interacts 
with the scaffold protein Raptor, and the AKT substrate 
PRAS40 (Kennedy, Lamming 2016). As shown in in Figure 
1, MTORC1 controls many processes, including protein 
synthesis, lipid synthesis, autophagy, mitochondrial metab-
olism, and biogenesis (Laplante, Sabatini 2009).  Many of 
the functions of mTORC1 are inhibited by acute exposure 
to rapamycin which causes a decrease in biosynthesis and 
an increase in biodegradation (Tee 2018, Hall 2017). 
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MTORC2 contains the scaffold protein Rictor, the 
protein subunits mSIN1 and Protor-1/2 (Laplante 2009). 
Prolonged rapamycin use inhibits mTORC2 by binding to 
free mTOR and preventing it from forming the mTORC2 
complex (Johnson et al. 2013, Sarbassov et al. 2006, Tee 
2018). MTORC2 is stimulated by IGF-1, insulin, and leptin 
(Kennedy, Lamming 2016).  MTORC2 regulates mTORC1 
via the phosphorylation of AKT. AKT phosphorylates 
TSC2, which is part of the TSC complex. TSC2 promotes 
the conversion of Rheb-GTP, which activates mTORC1 
to Rheb- GDP. Therefore, the phosphorylation of TSC2 
inhibits this conversion process, allowing the Rheb-
GTP complex to remain in its active form and activate 
mTORC1 (Manning, Toker 2017). AKT also phosphory-
lates PRAS40It, which is an inhibitor of mTORC1 in its 
unphosphorylated form (Sancak et al., 2007). The other 
regulatory functions of mTORC2 include regulating cell 
survival, metabolism, proliferation, and 
cytoskeleton organization (Laplante, 
Sabatini 2009). The pathways involving 
mTORC2 are outlined in Figure 2.
What Anti-Aging Effects does 
Rapamycin have on the Body?
MTORC1 controls many processes linked 
to aging. Therefore, the inhibition of these 
processes by rapamycin contribute to 
the drug’s anti-aging effects (Johnson et 
al. 2013). The suggested mechanisms of 
reduced aging by mTORC1 inhibition are 
discussed in this section. 
MTORC1 inhibition promotes autophagy, 
which is the recycling of amino acids and 
degradation of damaged macromolecules 
and organelles.  Autophagy in the cells 
declines with age, and it is proposed that 
the accumulation of damaged particles 
contribute to cellular dysfunction of aged 
individuals (Cuervo 2008).  MTROC1 in-
hibition promotes autophagic mediated 
longevity, as supported by studies on yeast 
and invertebrate (Johnson et al 2013).
Regulation of mRNA translation is an-
other process that may contribute to the 
anti-aging benefits of rapamycin. Under 
favorable growth conditions, mTROC1 
promotes mRNA translation and protein 
synthesis. Inhibition of mTORC1 reduces 
translation, and studies on yeast, nema-
todes, fruit flies, and mice provide evidence 
that regulation of mRNA translation in-
creases lifespan (Kaeberlein, Kennedy 2011). A main rea-
son for the increased lifespan accompanying global mRNA 
translation reduction is the differential protein translation 
of specific mRNA. Molecular evidence is seen in yeast; 
when mTORC1 is inhibited Gcn4 is preferentially trans-
lated and increased translation of Gcn4 increases lifespan. 
Similar mechanisms are seen in studies of nematodes and 
fruit flies (Johnson et al 2013).
Another function possibly contributing to the anti-ag-
ing benefit of rapamycin is reduced inflammation through 
mTORC1 inhibition. Hyperactivation of mTORC1 causes 
inflammation which is present in many age-related dis-
eases such as kidney disease, vascular inflammation after 
angioplasty, atherosclerotic plaques, and lung infection. 
Therefore, rapamycin use reduces inflammation associated 
with these diseases. (Johnson et al 2013).
Additionally, studies on yeast link mTORC1 inhibition to 
Figure 1. Diagram of the pathways involving mTORC1 (Kennedy, Lamming 2016)
Figure 2. Diagram of the pathways involving mTORC2 (Kennedy, Lamming 2016)
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the activation of a stress response pathway. The increased 
stress resistance promotes lifespan extension. Also, regu-
lation of mitochondrial function and enhanced stem cell 
function seem to contribute to the longevity effects of 
rapamycin (Johnson et al 2013). 
Rapamycin Studies on Mammals
The 2009 study conducted by Harrison et al. on 1,901 mice 
provides evidence for the longevity effects of rapamycin on 
mammals. In comparison to the control group, rapamycin- 
fed female mice had a 13% lifespan extension, and male 
mice had a 9% lifespan extension. The average age of the 
mice was 600 days, which is the equivalence of 60 years in 
humans. Thus, the study demonstrates rapamycin’s effec-
tiveness when started late in the lifespan. 
In 2019 Sills et al. studied the safety of rapamycin on 23 
middle-aged marmosets who were fed rapamycin for nine 
months. The marmoset showed no significant side effects 
and only minor effects on hematological markers.  Since 
marmosets are biologically similar to humans, the study 
suggest similar outcomes would occur in humans. 
Rapamycin Side Effects in Humans
Although rapamycin has been found to increase the lifes-
pan of flies, mice, and marmosets, few studies have tested 
its anti-aging effect on humans (Graziotto et al. 2012). This 
section will review negative side effects of rapamycin treat-
ment and the evidence to support the drug as an anti-aging 
therapy for humans. 
Many studies on rapamycin have been conducted on im-
munocompromised patients. Side effects of renal and heart 
transplant patients taking rapamycin for its immunosup-
pressive property include delayed wound healing, intersti-
tial pneumonitis, anemia, high cholesterol and triglyceride 
levels, infection, edema, and gastrointestinal symptoms. 
(Baur et al. 2011, Ekberg et al. 2010, Graziotto et al. 2012). 
Long term side effects of rapamycin include glucose intol-
erance, decreased insulin sensitivity, and increased risk of 
new onset diabetes (Johnston et al. 2008, Lamming 2016). 
While these reported side effects may seem to outweigh 
the potential benefits of rapamycin, it is important to con-
sider that the adverse effects may be influenced by the 
patients’ underlying condition or drug interactions (Kraig 
et al. 2018).
A small-scale study found that short term everolimus 
treatment boosted the immune response of normal, elderly 
individuals to the flu vaccine. This suggests that rapamycin 
improves immunosenescence, one characteristic of aging. 
Since rapamycin is also known for its immunosuppressive 
properties, its effects on the immune system seem to be de-
pendent on disease, age, and/or antigen (Mannick et al. 2014).
 Another small-scale study of a similar population found 
rapamycin use safe for elderly individuals with stabilized 
medical conditions. This population did not show a signifi-
cant change in plasma glucose, insulin, and insulin sensitivity, 
which contrasts with the increased risk of diabetes seen 
with transplant patients. Additionally, there was no significant 
elevation in triglyceride levels, which was also a concerning 
side effect seen in previous studies. The side-effects report-
ed in the study group were limited to a facial rash and GI 
symptoms. However, the study did not reveal any change 
in cognitive functioning, physical performance, or immune 
parameters. While these results do not support the anti-ag-
ing benefits of rapamycin, the limited side-effects on normal 
individuals support the safety of rapamycin use for further 
clinical testing (Kraig et al. 2018). 
Despite the promising results of life extension seen in 
mammals, only a limited number of clinical trials with small 
sample sizes were conducted on humans. Therefore, rapa-
mycin must undergo further studies to determine its efficacy. 
Conclusion/Further Research
The substantial side-effects associated with rapamycin 
use in transplant patients makes it difficult for it to be 
approved as a preventative aging treatment. However, 
the discovery of life extension by inhibiting mTOR pro-
vides a basis for the search of other anti-aging treatments 
that work by a similar mechanism. One suggestion is 
MTORC1 specific- inhibition, which is sufficient to extend 
lifespan and may have reduced side effects. Studies have 
demonstrated the importance of mTORC2 in human 
physiology and metabolism (Lamming et al. 2016). For 
example, mTORC2 plays an important role in B-Cells, 
T-cell and macrophages (Byles et al. 2013, Festuccia et al. 
2014). Additionally, prolonged ex-vivo exposure to rapa-
mycin inhibits lipogenesis in rat hepatocyte which can be 
attributed to the disruption of mTORC2 (Brown et al. 
2007, Kennedy, Lamming 2016). 
Kennedy and Lamming found that while chronic expo-
sure to FKBP12-rapamycin complex inhibits mTORC2, 
chronic exposure to the rapamycin-FKBP51 complex 
does not inhibit mTORC2. The binding affinity of rapa-
mycin with FBPK51 has an inverse relationship with the 
inhibition of mTROC2. Therefore, a rapamycin analog 
with a strong affinity for FKPB51 should be studied as a 
mTORC1 specific inhibitor (2016). 
Another possibility, which is not well-studied, is to har-
ness the benefits of rapamycin by eating a low-protein 
diet. Amino acids are one of the stimuli for mTORC1, 
but not mTROC2 (Lamming 2016). Studies show leucine 
consumption affects mTORC1 activity in humans, and a 
short-term protein-free diet reduces mTORC1 signaling 
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(Moberg et al. 2014, Harputlugil et al. 2014). The branch- 
chain amino acids - leucin, isoleucine and valine – enhance 
the mTORC1 activity in skeletal muscle, liver, pancreas 
and adipose tissue in rodents. Therefore, a diet with lim-
ited proteins or specific amino acids may provide a more 
natural approach to reduce aging (Lamming 2016).
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